Benralizumab

Description

This page contains brief details about the drug benralizumab, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Benralizumab is an antiasthmatic drug developed by the U.S. Food And Drug Administration and initially approved in Nov 2017 for treating severe eosinophilic asthma.

Mechanism of Action of Benralizumab

Benralizumab works by binding to a specific protein called interleukin-5 receptor alpha (IL-5Rα) on the surface of eosinophils, a type of white blood cell that plays a key role in the inflammation and narrowing of the airways in asthma. By binding to IL-5Rα, this drug reduces the number of eosinophils in the blood and airways, helping to decrease airway inflammation and improve asthma symptoms.

Uses of Benralizumab

Benralizumab is used to treat severe eosinophilic asthma, a subtype of asthma caused by high levels of eosinophils in the blood and airways. It is also approved for treating eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease affecting blood vessels and organs.

Benralizumab Dosage available

Benralizumab will be given by injection under the skin (subcutaneous). Your doctor, nurse, or other healthcare professional will show you how to inject the medicine. Do not try to administer the medicine if you are well-trained. Your physician will decide the injection dose based on your disease condition and severity.